Complications of Uncontrolled Diabetes: Multisystem Pathophysiology and Prevention

Chronic hyperglycemia drives microvascular and macrovascular complications through shared pathogenic pathways: advanced glycation end-products (AGEs), polyol pathway flux, PKC activation, hexosamine pathway, and oxidative stress.

Microvascular Complications

  • Retinopathy: Non-proliferative (microaneurysms, dot-blot hemorrhages, hard exudates) → proliferative (neovascularization, vitreous hemorrhage, tractional retinal detachment). Leading cause of blindness in working-age adults. Screening: Annual dilated exam (Type 1: 5yr post-dx; Type 2: at dx).
  • Nephropathy: Hyperfiltration → microalbuminuria (30-300 mg/g Cr) → macroalbuminuria (>300) → declining GFR → ESRD. ACEi/ARB first-line for albuminuria + BP control.
  • Neuropathy: Distal symmetric polyneuropathy (stocking-glove), autonomic (gastroparesis, orthostatic hypotension, ED, neurogenic bladder), mononeuropathies. Screen annually (monofilament, vibration, symptoms).

Macrovascular Complications

  • ASCVD: 2-4x risk MI, stroke, PAD. Mechanisms: endothelial dysfunction, accelerated atherosclerosis, prothrombotic state. Statin indicated for most >40yo.
  • Heart failure: Diabetic cardiomyopathy (diastolic dysfunction, fibrosis) independent of CAD.

Other Complications

  • Skin: Necrobiosis lipoidica, diabetic dermopathy, acanthosis nigricans, infections (fungal, bacterial), delayed wound healing
  • Dental: Periodontitis (bidirectional with glycemic control)
  • Sexual: ED (men: 3x risk), female sexual dysfunction
  • Pregnancy: GDM → macrosomia, shoulder dystocia, neonatal hypoglycemia, congenital anomalies (preconception HbA1c <6.5%)
  • Cognitive: Accelerated decline, vascular dementia, Alzheimer's link
  • Infections: Impaired neutrophil function; mucormycosis (DKA), emphysematous pyelonephritis

Prevention Framework (ADA Standards of Care)

  1. Glycemic targets: HbA1c <7% individualized; TIR >70% (CGM)
  2. BP control: <130/80 mmHg
  3. Lipids: High-intensity statin for 40-75yo; LDL <70 (ASCVD), <55 (very high risk)
  4. Antiplatelet: Aspirin 75-162mg for secondary prevention; select primary
  5. SGLT2i/GLP-1 RA: Cardiorenal benefits independent of glucose
  6. Screening schedule: Eye, foot, kidney, neuropathy annually
  7. Lifestyle: Mediterranean/DASH diet, 150 min/week activity, smoking cessation, weight management

Multidisciplinary care (endo, PCP, ophthalmology, podiatry, nephrology, cardiology, diabetes education) reduces complication incidence by 50-70% in trial settings.

Diabetes - Related Articles